He hasn't found his power swing at Memphis yet but he's still hitting
He hasn't found his power swing at Memphis yet, but he's still hitting the ball with authority. He's 21-years-old and has a tremendous amount of upside with the bat and glove. He's made only five errors behind the plate in the 35 games that he's played at Memphis.Ottavino is a first round draft pick from 2006 and is pitching well. He is a dominant pitcher and could be a very good starter in 2010 and lights out in 2011. He too could flourish in Cleveland with the right tutelage.Jess Todd is climbing the minor league ladder quickly and throws gas. He could flourish in Cleveland.Thompson is somewhat the same way He believes in Duncan's methods and LaRussa likes him.
Thompson is just having problems with people out performing him in the pen, and he isn't quite up to standards yet for the rotation. He and Tony LaRussa obviously don't click and Reyes doesn't believe in Dave Duncan's methods. Reyes still has a great arm and a tremendous amount of upside. Sabathia, 3B Wes Hodges, SS Josh Rodriguez.Ok, lets break this down from the Indians side of view.Reyes is in need of a change of scenery. Lets look at the proposed deal and how it breaks down for both sides, and then I'll show you some financials.Cleveland Indians receive: RHP Anthony Reyes, RHP Brad Thompson, RHP Jess Todd, RHP Adam Ottavino, C Bryan Anderson, 2B Jarrett Hoffpauir, OF Shane Robinson.St Louis Cardinals receive: LHP C.C. Sabathia wants Barry Zito and Johan Santanna type money and the Indians just don't have it.Do the Cardinals? Amazingly, yes.The Cardinals do have enough money to pull of this trade and sign Sabathia long term. Adam Wainwright's finger may linger longer than hoped and Chris Carpenter may not come back to the rotation for a while, if not until 2009 C.C.
Sabathia provides that cushion for the current Cardinals rotation and adds a power arm for the playoff push.The Cleveland Indians have not said that they are going to trade Sabathia immediately, but everyone knows it's only a matter of time. Lets face it: the Cardinals need a reliable ace in the rotation. The only problem is the need to get more runs on the board and finds a starter who has the desire and commitment Lidge does.That's going to win ball games.. Has this happened? No, not really, but it definitely could happen sometime in the next month. Copyright 2009, Market Wire, All rights reserved.-0-. Investors are cautioned thatforward-looking statements are not guarantees of future performance andaccordingly investors are cautioned not to put undue reliance onforward-looking statements due to the inherent uncertainty therein.Lorus Therapeutics Inc.'s recent press releases are available through theCompany's website at For Lorus' regulatory filings onSEDAR, please go to For SEDAR filings prior to July 10,2007 you will find these under the company profile for Global Summit RealEstate Inc (Old Lorus).Contacts:Lorus Therapeutics Inc.Dr Saeid Babaei416-798-1200 ext.
These forward-looking statements are made as of the date of thispress release and we do not intend, and do not assume any obligation, toupdate these forward-looking statements, except as required by law. Wecannot assure you that such statements will prove to be accurate asactual results and future events could differ materially from thoseanticipated in such statements. Such statements reflect our current views withrespect to future events and are subject to risks and uncertainties andare necessarily based upon a number of estimates and assumptions that,while considered reasonable by us are inherently subject to significantbusiness, economic, competitive, political and social uncertainties andcontingencies. Such statements include,but are not limited to, statements relating to: our research programplans, our plans to conduct clinical trials, the successful and timelycompletion of clinical studies and the regulatory approval process, ourability to fund future research, our plans to obtain partners to assistin the further development of our product candidates, the establishmentof corporate alliances, the Company's plans, objectives, expectations andintentions and other statements including words such as "continue","believe", "plan", "expect", "intend", "will", "should", "may", and othersimilar expressions.
Through itsown discovery efforts and an acquisition and in-licensing program, Lorusis building a portfolio of promising anticancer drugs Lorus TherapeuticsInc. is listed on the Toronto Stock Exchange under the symbol LOR.Forward Looking StatementsThis press release may contain forward-looking statements within themeaning of Canadian and U.S securities laws. Lorus' goal is to capitalizeon its research, preclinical, clinical and regulatory expertise bydeveloping new drug candidates that can be used, either alone, or incombination with other drugs, to successfully manage cancer. The R2 target hasbeen described as a malignant determinant that is elevated in a widerange of tumor types, which can cooperate with a variety of cellularcancer causing genes known as oncogenes to enhance tumor growth andmetastatic potential.About LorusLorus is a biopharmaceutical company focused on the research anddevelopment of novel therapeutics in cancer. Through downregulation of R2, LOR-2040has demonstrated strong antitumor and antimetastatic activity in avariety of tumor types in both in vitro and in vivo models and is understudy in a multiple Phase I/II clinical program, including an advancedPhase II clinical trial with LOR-2040 and high dose Ara-C (HiDAC) inrefractory and relapsed Acute Myeloid Leukemia (AML). "We are pleased that the studyresults by our OSU collaborators support this combination strategy. Webelieve these findings help to strengthen our clinical program withLOR-2040 in relapsed/refractory AML".About LOR-2040LOR-2040 is an RNA-targeted drug that specifically targets the R2component of ribonucleotide reductase, which is required for DNAsynthesis and cell proliferation.